Galiano R D, Zhao L L, Clemmons D R, Roth S I, Lin X, Mustoe T A
Division of Plastic and Reconstructive Surgery, Northwestern University Medical School, Chicago, Illinois 60611, USA.
J Clin Invest. 1996 Dec 1;98(11):2462-8. doi: 10.1172/JCI119064.
We have determined previously that IGF-I is dependent on the presence of IGF binding protein-1 (IGFBP-1) to act as a wound healing agent. We sought to determine the mechanism whereby IGFBP-1 is able to enhance IGF-I bioactivity. As IGFBP-1 binds both the alpha5beta1 integrin as well as IGF-I in vitro, we asked which of the following interactions were important: (a) the ability of IGFBP-1 to interact with an integrin receptor, and/or (b) the binding of IGF-I by IGFBP-1. We used an IGF-1 analogue (des(1-3)IGF-I) with a > 100-fold reduction in affinity for IGFBP-1 as well as an IGFBP-1 mutant (WGD-IGFBP-1) which does not associate with the alpha5beta1 integrin to selectively abrogate each of these interactions. We also tested the ability of IGFBP-2, a related binding protein which has an arginine-glycine-aspartate sequence but does not associate with integrin family members, to enhance IGF-I bioactivity. Full-thickness dermal wounds were created on rabbit ears; various combinations of native IGF-I, native IGFBP-1, native IGFBP-2, and their respective analogues/mutants were applied to each wound. Wounds were harvested 7 d later for analysis. Only native IGF-I in combination with native IGFBP-1 was effective as a wound healing agent, enhancing reepithelialization and granulation tissue deposition by 64+/-5 and 83+/-12% over controls (P = 0.008 and 0.016, respectively). The same doses of IGF-I/WGD-IGFBP-1, des(1-3)IGF-I/IGFBP-1, and IGF-I/IGFBP-2 were ineffective. We propose that IGF-I physically interacts with IGFBP-1 and that IGFBP-1 also binds to an integrin receptor, most likely the alpha5beta1 integrin. This interaction is unique to IGFBP-1 as the closely related IGFBP-2 had no effect, a finding consistent with its inability to bind to integrin receptors. Our results suggest that activation of both the IGF-I receptor and the alpha5beta1 integrin is required for IGF-I to stimulate wound healing.
我们之前已经确定,胰岛素样生长因子-I(IGF-I)作为一种伤口愈合剂发挥作用依赖于胰岛素样生长因子结合蛋白-1(IGFBP-1)的存在。我们试图确定IGFBP-1能够增强IGF-I生物活性的机制。由于IGFBP-1在体外既能结合α5β1整合素又能结合IGF-I,我们探究以下哪种相互作用是重要的:(a)IGFBP-1与整合素受体相互作用的能力,和/或(b)IGFBP-1对IGF-I的结合。我们使用了一种对IGFBP-1亲和力降低超过100倍的IGF-1类似物(去(1-3)IGF-I)以及一种不与α5β1整合素结合的IGFBP-1突变体(WGD-IGFBP-1)来选择性消除这些相互作用中的每一种。我们还测试了胰岛素样生长因子结合蛋白-2(IGFBP-2)增强IGF-I生物活性的能力,IGFBP-2是一种相关的结合蛋白,具有精氨酸-甘氨酸-天冬氨酸序列但不与整合素家族成员结合。在兔耳上制造全层皮肤伤口;将天然IGF-I、天然IGFBP-1、天然IGFBP-2及其各自的类似物/突变体的各种组合应用于每个伤口。7天后收获伤口进行分析。只有天然IGF-I与天然IGFBP-1的组合作为伤口愈合剂有效,与对照组相比,上皮再形成和肉芽组织沉积分别增加了64±5%和83±12%(P分别为0.008和0.016)。相同剂量的IGF-I/WGD-IGFBP-1、去(1-3)IGF-I/IGFBP-1和IGF-I/IGFBP-2无效。我们提出IGF-I与IGFBP-1发生物理相互作用,并且IGFBP-1也与一种整合素受体结合,最有可能是α5β1整合素。这种相互作用是IGFBP-1所特有的,因为密切相关的IGFBP-2没有效果,这一发现与其无法结合整合素受体一致。我们 的结果表明,IGF-I刺激伤口愈合需要激活IGF-I受体和α5β1整合素。